���沙莫瑞林历史与监管定位 — Beginner to Advanced

By Editorial Desk · published 2025-08-09 · last reviewed 2025-09-07 · Blog

A practical reference on lyophilized peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.

特沙莫瑞林历史与监管定位

在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。

特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。

监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。

Biological Role and Origin

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.

The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.

Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.

Tesamorelin at a glance

Tesamorelin Identity And Structure

The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.

Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.

Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.

Related pages on this site

• Clear trends
• Comprehensive overview
• Optimized guide
• Simple summary
• Technical collection
• Clear workbook
• Modern primer
• Scheduled comparison

Background and Receptor Mechanism

Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.

Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.

Background and Pharmacology of Tesamorelin

Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.

Background And Regulatory Development

Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.

Notes from published material

Narrated by Robin Ellis, produced by Rachel Allen, directed by Sarah Marris, made by TVF Media 24 May Storm in a D Cup, about breast implants; Sally Kirkland was a main protagonist against implants; Sybil Niden Goldrich of the Command Trust Network; Marcia Angell of The New England Journal of Medicine; the British 1990s glamour model Teresa May; Roger Sturrock of the University of Glasgow; Dennis Deapen of the University of Southern California; Sai Ramastry of the University of Illinois Chicago; British 1990s glamour model Hannah Callow sat nonchalantly on a London underground train, with surreptitious nearby male attention. Directed by Martin Durkin (often chose quite controversial topics), made by his company Kugelblitz 7 June Curse of the Phantom Limbs, about sensations of phantom limbs; Jackie Naylor lost her hand in an accident on the A57 in 1989; neuroscientist Peter Halligan, since 2018 the Chief Scientific Adviser for Wales; photographer Alexa Wright makes superfiction images of phantom limbs; the Douglas Bader Centre at the Queen Mary's Hospital, Roehampton; Canadian psychologist Ronald Melzack of McGill University; Conrad Weiskrantz, son of neuroscientist Lawrence Weiskrantz had a motorbike accident on a country road, where he hit a vehicle towing a trailer turning right; the Silver Spring monkeys; neuroscientist V. S. Ramachandran of University of California, San Diego; Canadian neurosurgeon Wilder Penfield conducted cortical stimulation mapping research in the 1950s, resulting in the cortical homunculus and cortical maps; neurosurgeon Tipu Aziz.

=== Human clinical studies === In human clinical studies, epitalon and epithalamin both significantly increased telomere lengths in the blood cells of patients of ages 60-65 and 75-80, and their efficacy was comparable to one another. Epitalon and epithalamin appear to restore melatonin secretion by the pineal gland in both aged monkeys and humans. A human clinical trial conducted on a sample of retinitis pigmentosa patients found that epitalon produced a positive clinical effect in 90% of cases in the treated group. In another human clinical trial conducted on a sample of pulmonary tuberculosis patients, epitalon did not appear to correct pre-existing structural aberrations of chromosomes associated with telomere degradation, but did appear to exert a protective effect against the future development of additional chromosomal aberrations. A human prospective cohort study conducted on a sample of 266 people over age 60 demonstrated that treatment with epithalamin, the pineal gland extract upon which epitalon is based, produced a 1.6–1.8-fold reduction in mortality during the following 6 years, a 2.5-fold reduction in mortality when combined with thymalin, and a 4.1-fold reduction in mortality when combined with thymalin and administered annually instead of only once at study onset.

==== Australia ==== Salvinorin A is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

== Medical uses == People with Pompe disease have an enzyme deficiency that leads to the accumulation of a complex sugar, called glycogen, in skeletal and heart muscles, which causes muscle weakness and premature death from respiratory or heart failure. Avalglucosidase alfa is indicated for the treatment of people aged one year and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).

== See also == List of acts of the 117th United States Congress Procedures of the U.S. Congress List of United States federal legislation List of executive actions by Joe Biden List of impeachment resolutions introduced against Donald Trump

Sources: en.wikipedia.org

Background from the literature

The exterior of an individual segment is a thin cuticle over the skin, commonly pigmented red to brown, which has specialized cells that secrete mucus over the cuticle to keep the body moist and ease movement through the soil. Under the skin is a layer of nerve tissue, and two layers of muscles—a thin outer layer of circular muscle, and a much thicker inner layer of longitudinal muscles. Interior to the muscle layer is a fluid-filled chamber called a coelom that by its pressurization provides structure to the worm's boneless body. The segments are separated from each other by septa (the plural of "septum") which are perforated transverse walls, allowing the coelomic fluid to pass between segments. A pair of structures called nephrostomes are located at the back of each septum; a nephric tubule leads from each nephrostome through the septum and into the following segment. This tubule then leads to the main body fluid filtering organ, the nephridium or metanephridium, which removes metabolic waste from the coelomic fluid and expels it through pores called nephridiopores on the worm's sides; usually, two nephridia (sometimes more) are found in most segments. At the centre of a worm is the digestive tract, which runs straight through from mouth to anus without coiling, and is flanked above and below by blood vessels (the dorsal blood vessel and the ventral blood vessel as well as a subneural blood vessel) and the ventral nerve cord, and is surrounded in each segment by a pair of pallial blood vessels that connect the dorsal to the subneural blood vessels.

The half-lives of nuclei in the island of stability itself are unknown since none of the nuclides that would be "on the island" have been observed. Many physicists believe that the half-lives of these nuclei are relatively short, on the order of minutes or days. Some theoretical calculations indicate that their half-lives may be long, on the order of 100 years, or possibly as long as 109 years. The shell closure at N = 184 is predicted to result in longer partial half-lives for alpha decay and spontaneous fission. It is believed that the shell closure will result in higher fission barriers for nuclei around 298Fl, strongly hindering fission and perhaps resulting in fission half-lives 30 orders of magnitude greater than those of nuclei unaffected by the shell closure. For example, the neutron-deficient isotope 284Fl (with N = 170) undergoes fission with a half-life of 2.5 milliseconds, and is thought to be one of the most neutron-deficient nuclides with increased stability in the vicinity of the N = 184 shell closure. Beyond this point, some undiscovered isotopes are predicted to undergo fission with still shorter half-lives, limiting the existence and possible observation of superheavy nuclei far from the island of stability (namely for N < 170 as well as for Z > 120 and N > 184). These nuclei may undergo alpha decay or spontaneous fission in microseconds or less, with some fission half-lives estimated on the order of 10−20 seconds in the absence of fission barriers.

== Selected articles == McCartney, Fiona; Jannin, Vincent; Chevrier, Stéphanie; Boulghobra, Hakime; Hristov, Delyan R.; Ritter, Nicolas; Miolane, Cédric; Chavant, Yann; Demarne, Frédéric; Brayden, David J. (2019). "Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies". Journal of Controlled Release. 310: 115–126. doi:10.1016/j.jconrel.2019.08.008. PMID 31401199. Hristov, Delyan; McCartney, Fiona; Beirne, Jason; Mahon, Eugene; Reid, Stephanie; Bhattacharjee, Sourav; Penarier, Geraldine; Werner, Ulrich; Bazile, Didier; Brayden, David J. (2020). "Silica-coated nanoparticles with a core of zinc, l-Arginine, and a peptide designed for oral delivery". ACS Applied Materials & Interfaces. 12 (1): 1257–1269. Bibcode:2020AAMI...12.1257H. doi:10.1021/acsami.9b16104. PMID 31802658. Twarog, Caroline; Liu, Kai; O'Brien, Peter J.; Dawson, Kenneth A.; Fattal, Elias; Illel, Brigitte; Brayden, David J. (2020). "A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10)". European Journal of Pharmaceutics and Biopharmaceutics. 152: 95–107. doi:10.1016/j.ejpb.2020.04.023. PMID 32387703. Khandelia, Rumi; Hodgkinson, Tom; Crean, Daniel; Brougham, Dermot F.; Scholz, Dimitri; Ibrahim, Hossam; Quinn, Susan J.; Rodriguez, Brian J.; Kennedy, Oran D.; O’Byrne, John M.; Brayden, David J. (2024). "Reproducible synthesis of biocompatible albumin nanoparticles designed for intra-articular administration of celecoxib to treat osteoarthritis".

The nape and the anterior third of the body have irregular pale brown and black cross bars, the black forming rings on the neck. The upper lip is pale brown, with black lines on the sutures between the shields. The lower surface of the head is brownish white. The belly and the ventral surface of the tail are blackish.

Sources: en.wikipedia.org

Reference notes

Picamilon (also known as N-nicotinoyl-GABA, pycamilon, and pikamilon) is a drug formed by a synthetic combination of niacin and γ-aminobutyric acid (GABA). It was developed in the Soviet Union in 1969 and further studied in both Russia and Japan as a prodrug of GABA. In Russia, picamilon is sold as a prescription drug. The rights to the drug belong to the Russian pharmaceutical company NPK ECHO ("НПК ЭХО"). It is not approved for sale in the United States and has been deemed an adulterating agent in dietary supplements, with five American companies required to remove their picamilon products from the market in November 2015. However, as recently as 2020, picamilon has been found in pharmaceutical dosages in over-the-counter supplements in the US.

Blue fluorescent protein (BFP) is the blue variant of green fluorescent protein (GFP). BFP has a very similar structure to GFP. In the BFP structure, two substitution mutations in the amino acid sequence change its fluorescence from green to blue. The first mutation occurs inside the chromophore of GFP at position 66 which changes a tyrosine to a histidine. The other mutation in BFP is on the tyrosine at position 145 which mutates to phenylalanine. The autocatalytic cyclization and oxidation of the serine, tyrosine, and glycine form the GFP chromophore. These three residues at positions 65-67 make up the green fluorescent chromophore. When the tyrosine in the chromophore is substituted by a histidine, it changes the folding structure of the protein and emission spectra. The T145F mutation is also added to increase the stability of the protein and well as intensify the fluorescence. These mutations are what change GFP to BFP.

== Biomembranes and phospholipid bilayers == Biological membranes are found in both prokaryotic and eukaryotic cells. They surround cells and organelles with a semi-permeable barrier that prevents free flow of substances. The membrane consists of a phospholipid bilayer structure and often embedded or otherwise associated proteins, along with cholesterol and glycolipids. The phospholipid bilayer is a two-layer structure mainly composed of phospholipids, which are amphiphilic molecules that have hydrophilic and hydrophobic regions. The hydrophilic region contains the polar head group. This region is exposed to aqueous substances located mainly in the exterior portion of the biomembrane. The hydrophobic region consists of the non-polar acyl chains or fatty acids groups facing the interior of the biomembrane. Phospholipids consist of two non-polar hydrocarbon chains with ester or ether bonds to the phosphate group which is also linked by ester or ether bonds to the polar hydrophilic region. The phospholipid carries a negative charge due to the presence of the phosphate group. Its overall polarity depends on the charges of the hydroxyl groups or alcohols such as choline, ethanolamine, inositol, serine, etc. attached to the phosphate group. There are six basic functions that are associated with biomembranes:

== ISO 4500 - ISO 4999 == ISO 4548 Methods of test for full-flow lubricating oil filters for internal combustion engines ISO 4548-7:2012 Part 7: Vibration fatigue test ISO 4551:1987 Ferroalloys – Sampling and sieve analysis ISO 4552 Ferroalloys – Sampling and sample preparation for chemical analysis ISO 4552-1:1987 Part 1: Ferrochromium, ferrosilicochromium, ferrosilicon, ferrosilicomanganese, ferromanganese ISO 4552-2:1987 Part 2: Ferrotitanium, ferromolybdenum, ferrotungsten, ferroniobium, ferrovanadium ISO 4570 Tyre valve threads ISO 4578 Adhesives — Determination of peel resistance of high-strength adhesive bonds — Floating-roller method ISO 4582 Plastics — Determination of changes in colour and variations in properties after exposure to daylight under glass, natural weathering or laboratory light sources ISO 4587 Adhesives — Determination of tensile lap-shear strength of rigid-to-rigid bonded assemblies ISO 4618:2014 Paints and varnishes – Terms and definitions ISO 4628 Paints and varnishes – Evaluation of degradation of coatings – Designation of quantity and size of defects, and of intensity of uniform changes in appearance ISO 4628-1 General introduction and designation system ISO 4628-2 Assessment of degree of blistering ISO 4628-3 Assessment of degree of rusting ISO 4628-4 Assessment of degree of cracking ISO 4628-5 Assessment of degree of flaking ISO 4628-6 Assessment of degree of chalking by tape method ISO 4628-7 Assessment of degree of chalking by velvet method ISO 4628-8 Assessment of degree of delamination and corrosion around a scribe ISO 4628-10 Assessment of degree of filiform corrosion ISO 4648:1991 Rubber, vulcanized or thermoplastic — Determination of dimensions of test pieces and products for test purposes [Withdrawn: replaced with ISO 23529] ISO 4661 Rubber, vulcanized — Preparation of samples and test pieces ISO 4661-1:1993 Rubber, vulcanized or thermoplastic — Preparation of samples and test pieces — Part 1: Physical tests [Withdrawn: replaced with ISO 23529] ISO 4661-2:2018 Rubber, vulcanized — Preparation of samples and test pieces — Part 2: Chemical tests ISO 4683 Raw sheep skins ISO 4683-1:1998 Part 1: Descriptions of defects ISO 4720:2009 Essential oils – Nomenclature ISO 4730:2017 Essential oil of Melaleuca, terpinen-4-ol type (Tea Tree oil) ISO 4786:1977 Enclosed-scale adjustable-range thermometers [Withdrawn without replacement] ISO 4787:2010 Laboratory glassware – Volumetric instruments – Methods for testing of capacity and for use ISO 4788:2005 Laboratory glassware – Graduated measuring cylinders ISO 4791 Laboratory apparatus – Vocabulary relating to apparatus made essentially from glass, porcelain or vitreous silica ISO 4791-1:1985 Part 1: Names for items of apparatus ISO 4795:1996 Glass for thermometer bulbs ISO 4801:1979 Glass alcoholometers and alcohol hydrometers not incorporating a thermometer ISO 4805:1982 Laboratory glassware – Thermo-alcoholometers and alcohol-thermohydrometers ISO 4824:1993 Dentistry — Ceramic denture teeth [Withdrawn: replaced with ISO 22112] ISO 4831:2006 Microbiology of food and animal feeding stuffs – Horizontal method for the detection and enumeration of coliforms – Most probable number technique ISO 4832:2006 Microbiology of food and animal feeding stuffs – Horizontal method for the enumeration of coliforms – Colony-count technique ISO 4833 Microbiology of the food chain – Horizontal method for the enumeration of microorganisms ISO 4833-1:2013 Part 1: Colony count at 30 degrees C by the pour plate technique ISO 4833-2:2013 Part 2: Colony count at 30 degrees C by the surface plating technique ISO 4848:1980 Concrete — Determination of air content of freshly mixed concrete — Pressure method [Withdrawn: replaced with ISO 1920-2] ISO 4858:1982 Wood — Determination of volumetric shrinkage [Withdrawn: replaced with ISO 13061-14] ISO 4859:1982 Wood — Determination of radial and tangential swelling [Withdrawn: replaced with ISO 13061-15] ISO 4860:1982 Wood — Determination of volumetric swelling [Withdrawn: replaced with ISO 13061-16] ISO 4866:2010 Mechanical vibration and shock – Vibration of fixed structures – Guidelines for the measurement of vibrations and evaluation of their effects on structures ISO 4871:1996 Acoustics – Declaration and verification of noise emission values of machinery and equipment ISO/IEC 4873:1991 Information technology – ISO 8-bit code for information interchange – Structure and rules for implementation ISO 4875 Metal-cutting band saw blades ISO 4875-1:2006 Part 1: Vocabulary ISO 4880:1997 Burning behaviour of textiles and textile products – Vocabulary ISO 4882:1979 Office machines and data processing equipment – Line spacings and character spacings ISO 4885:2017 Ferrous materials – Heat treatments – Vocabulary ISO 4892 Plastics – Methods of exposure to laboratory light sources ISO 4902:1989 Information technology – Data communication – 37-pole DTE/DCE interface connector and contact number assignments ISO 4903:1989 Information technology – Data communication – 15-pole DTE/DCE interface connector and contact number assignments ISO/IEC 4909:2006 Identification cards – Financial transaction cards – Magnetic stripe data content for track 3 ISO 4921:2000 Knitting – Basic concepts – Vocabulary ISO/IEC 4922-1 Information security — Secure multiparty computation ISO/IEC 4922-1:2023 Part 1: General ISO 4977 Double cold-reduced electrolytic tinplate ISO 4977-1:1984 Part 1: Sheet [Withdrawn: replaced with ISO 11949] ISO 4977-2:1984 Part 2: Coil for subsequent cutting into sheets [Withdrawn: replaced with ISO 11949]

Pharmacometabolomics may decrease the burden on the healthcare system by better gauging the correct choice of treatment drug and dosage in order to optimize the response of a patient to a treatment. Hopefully, this approach will also ultimately limit the number of adverse drug reactions (ADRs) associated with many treatment regimens. Overall, physicians would be better able to apply more personalized, and potentially more effective, treatments to their patients. It is important to consider, however, that the processing and analysis of the patient samples takes time, resulting in delayed treatment. Another concern about the application of pharmacometabolomics analyses to individual patient care, is deciding who should and who should not receive this in-depth, personalized treatment protocol. Certain diseases and stages of disease would have to be classified according to their requirement of such a treatment plan, but there are no criteria for this classification. Furthermore, not all hospitals and treatment institutes can afford the equipment to process and analyze patient samples on site, but sending out samples takes time and ultimately delays treatment. Health insurance coverage of such procedures may also be an issue. Certain insurance companies may discriminate against the application of this type of sample analysis and metabolite characterization. Furthermore, there would have to be regulations put in place to ensure that there was no discrimination by insurance companies against the metabolic profiles of individual patients ("high metabolizers" vs.

Sources: en.wikipedia.org

Frequently asked questions